Rising Therapy-Related Leukemia Rates Signal New Testing Demands for Clinical Labs

A new population-based study, published in CANCER, a journal of the American Cancer Society, has brought into sharp focus a growing challenge for the global healthcare system, particularly for clinical laboratories: the escalating incidence of therapy-related acute myeloid leukemia (tAML). This secondary blood cancer, a severe consequence linked to prior chemotherapy and radiation exposure for primary cancers, is on a steady rise, creating a pressing demand for advanced diagnostic and surveillance strategies. The findings, derived from an extensive analysis of data spanning three decades, underscore a profound shift in the landscape of cancer care, where the triumphs of improved survival rates for primary cancers are now shadowed by the emergence of complex secondary malignancies.

Understanding Therapy-Related AML: A Paradox of Progress

Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid cells. While AML can arise spontaneously (de novo AML), a distinct and increasingly recognized subtype is tAML. Unlike its spontaneous counterpart, tAML is unequivocally linked to previous exposure to cytotoxic therapies—chemotherapy agents and radiation—used to treat an earlier, unrelated malignancy. This distinction is crucial, as tAML often presents with more aggressive clinical features, specific cytogenetic abnormalities, and a generally poorer prognosis compared to de novo AML.

The pathogenesis of tAML is rooted in the very mechanisms designed to eradicate primary cancers. Cytotoxic agents, while effective in destroying cancer cells, can also inflict damage upon the DNA of healthy hematopoietic stem cells in the bone marrow. This damage can lead to chromosomal aberrations, gene mutations, and ultimately, the malignant transformation of these cells into leukemic blasts. Common culprits include alkylating agents (such as cyclophosphamide, melphalan, and carmustine) and topoisomerase II inhibitors (like etoposide, doxorubicin, and mitoxantrone). The latency period between primary cancer treatment and tAML diagnosis can vary widely, typically ranging from a few months to several years, depending on the specific therapy received.

The Osaka Study: A Longitudinal Beacon

The latest research, meticulously conducted by scientists analyzing data from the Osaka Cancer Registry, provides one of the most comprehensive longitudinal insights into the evolving epidemiology of tAML. The study meticulously tracked nearly 10,000 AML cases diagnosed between 1990 and 2020 within the Osaka prefecture of Japan. The results are stark: 6.5% of all AML cases during this period were identified as therapy-related. More critically, the incidence of tAML showed a consistent and concerning upward trend, climbing from 0.13 cases per 100,000 people in the early 1990s to 0.36 cases per 100,000 by 2020. This translates to a near doubling of tAML’s proportion within the total AML burden over the study’s thirty-year span, highlighting a significant shift in disease demographics.

"The study provides an important step towards better understanding how the nature of tAML is changing with the increasing number of cancer survivors," noted lead author Kenji Kishimoto, MD, PhD, of the Osaka International Cancer Institute. His statement encapsulates the core message of the research: the success in treating primary cancers has inadvertently paved the way for a rise in secondary, often more challenging, malignancies.

The period from 1990 to 2020 witnessed revolutionary advancements in oncology. Throughout the 1990s, aggressive multi-agent chemotherapy regimens became standard for many solid tumors and hematologic malignancies. The 2000s saw the widespread adoption of targeted therapies and immunotherapies, often in combination with conventional cytotoxic agents, further improving survival rates. Concurrently, advancements in supportive care, including antiemetics, growth factors, and infection prophylaxis, enabled patients to tolerate more intensive treatments. These improvements, while laudable for extending life, also meant a larger population of long-term survivors, who, by virtue of their prior exposure to DNA-damaging agents, were at an elevated risk of developing tAML. The Osaka data serve as a crucial epidemiological marker, reflecting these global trends at a regional level.

The Rising Tide of Cancer Survivorship and its Unforeseen Consequences

The increase in tAML incidence is a direct, albeit unwelcome, consequence of modern oncology’s success. Globally, cancer survival rates have improved dramatically over the past few decades. For instance, the overall five-year relative survival rate for all cancers combined in the United States rose from 49% in the mid-1970s to 68% in 2013-2019. Similar trends are observed worldwide, driven by earlier detection, more effective treatments, and better supportive care. This growing population of cancer survivors, estimated to be in the tens of millions globally, represents a triumph of medical science. However, it also presents a new set of long-term health challenges, among which tAML is one of the most severe.

The implications extend beyond just tAML. Other therapy-related secondary malignancies, such as therapy-related myelodysplastic syndromes (tMDS) and secondary solid tumors, also contribute to the long-term morbidity of cancer survivors. These conditions collectively underscore the critical need for a holistic approach to cancer care that not only focuses on eradicating the primary tumor but also on mitigating and monitoring long-term treatment-related toxicities.

Evolving Precursor Cancers and Specific Risks

The Osaka study also shed light on the changing patterns of primary cancers that precede tAML. Historically, prior hematologic malignancies, such as lymphomas and multiple myeloma, have been significant precursors due to the intensive chemotherapy regimens often employed in their treatment. The study confirmed their continued prominence but highlighted a notable shift: cases of tAML following breast cancer treatment showed a significant increase over the study period. This trend is particularly salient given the high incidence of breast cancer and the widespread use of adjuvant chemotherapy, including regimens containing topoisomerase II inhibitors and alkylating agents, in its management. As breast cancer survival rates continue to improve, the sheer volume of survivors exposed to these therapies naturally elevates the overall risk of tAML within this population.

Conversely, while colorectal and gastric cancers were also represented as precursors, the incidence of tAML associated with gastric cancer declined. This could be attributed to several factors, including evolving treatment protocols for gastric cancer, potentially involving less myelotoxic agents, or earlier detection leading to less aggressive initial therapies. These shifts emphasize the dynamic interplay between treatment advancements for primary cancers and the subsequent risk profiles for secondary leukemias, underscoring the need for continuous reassessment of therapeutic regimens and their long-term effects.

A New Diagnostic Imperative for Clinical Laboratories

For clinical laboratories, the escalating rates of tAML translate into an urgent demand for enhanced capabilities and strategic adaptation. The findings from Osaka underscore that labs are increasingly likely to encounter complex secondary malignancies requiring highly sophisticated hematologic testing, advanced molecular profiling, and meticulous longitudinal monitoring.

Expanded Genomic Testing: tAML is characterized by distinct genetic signatures and chromosomal abnormalities that differ from de novo AML. Common cytogenetic aberrations include monosomy 5, monosomy 7, and complex karyotypes. At the molecular level, mutations in genes such as TP53, RUNX1, SRSF2, and CEBPA are frequently observed. Therefore, clinical laboratories must expand their genomic testing capabilities. This includes:
- Conventional Cytogenetics: Karyotyping remains essential for detecting gross chromosomal abnormalities.
- Fluorescence In Situ Hybridization (FISH): Targeted FISH panels can rapidly identify common recurrent abnormalities associated with tAML.
- Next-Generation Sequencing (NGS): Comprehensive NGS panels are crucial for identifying specific gene mutations that aid in diagnosis, prognostication, and, increasingly, in guiding targeted therapies. NGS can detect low-level clonal hematopoiesis, which may precede overt tAML, offering potential avenues for early intervention.
- Minimal Residual Disease (MRD) Monitoring: For tAML patients undergoing treatment, highly sensitive MRD assays (e.g., multiparameter flow cytometry, quantitative PCR, or NGS-based approaches) are vital for tracking treatment response and detecting relapse early.
Enhanced Surveillance Strategies: The rising incidence of tAML necessitates more robust and proactive surveillance protocols for cancer survivors. Clinical laboratories play a pivotal role in this. Routine complete blood counts (CBCs) with differential are fundamental for detecting cytopenias or unexplained leukocytosis that might signal early myelodysplastic changes or overt leukemia. However, given the often subtle initial presentation of tMDS/tAML, laboratories need to be prepared to perform more in-depth investigations, including bone marrow biopsies and specialized flow cytometry, based on clinical suspicion. The development and validation of novel biomarkers for early detection, perhaps through liquid biopsy approaches or advanced proteomics, represent a crucial area for future laboratory research and development.
Interdisciplinary Collaboration: The complexity of tAML demands seamless collaboration between clinical laboratories, oncologists, hematologists, and radiation oncologists. Lab professionals need to understand the patient’s prior treatment history, including specific chemotherapy agents, radiation fields, and cumulative doses, to guide appropriate testing. Conversely, clinicians rely heavily on accurate and timely laboratory results for diagnosis, risk stratification, and treatment planning. This necessitates robust communication channels and integrated clinical-pathological reviews.
Technological Investment and Workforce Development: To meet these evolving demands, clinical laboratories must invest in state-of-the-art instrumentation for molecular diagnostics, bioinformatics infrastructure for interpreting complex genomic data, and automation solutions to handle increasing test volumes. Equally critical is the continuous education and training of laboratory professionals—molecular pathologists, cytogeneticists, medical technologists, and bioinformaticians—to ensure they possess the specialized skills required for advanced hematologic and genomic testing.

Broader Impact on Healthcare Systems and Patient Care

The growing burden of tAML extends its ramifications across the entire healthcare ecosystem. For healthcare systems, it implies increased resource allocation for managing a challenging and often refractory disease. The treatment of tAML is typically intensive, prolonged, and costly, often requiring allogeneic stem cell transplantation, which comes with significant financial and human resource demands.

For patients, the development of tAML after surviving a primary cancer can be devastating. It represents a "second hit" that not only carries a poor prognosis but also profoundly impacts quality of life. Therefore, patient education regarding the potential long-term risks of cancer therapy is paramount. Oncologists face the delicate balance of delivering life-saving primary cancer treatments while minimizing the risk of secondary malignancies. This ongoing ethical and clinical dilemma fuels the imperative for research into less myelotoxic yet equally effective therapeutic agents and personalized treatment strategies that consider individual patient risk factors for tAML.

Looking Ahead: Shaping the Future of Oncology and Diagnostics

The Osaka study serves as a critical call to action, urging the global medical community to proactively address the rising tide of therapy-related malignancies. As cancer treatments continue to evolve, with an increasing focus on precision medicine, targeted therapies, and immunotherapies, there is hope that future regimens may carry a lower risk of secondary leukemogenesis. However, for the millions of survivors treated with conventional cytotoxic agents, the risk of tAML remains a tangible concern.

The clinical laboratory stands at the forefront of this challenge. By embracing advanced genomic technologies, developing sophisticated surveillance protocols, fostering interdisciplinary collaboration, and investing in continuous innovation, laboratories can play an indispensable role in improving the early detection, accurate diagnosis, and ultimately, the outcomes for patients afflicted with therapy-related acute myeloid leukemia. The ongoing commitment to population-based registries and long-term epidemiological studies, exemplified by the Osaka Cancer Registry, will remain vital for monitoring these trends and guiding future strategies in cancer prevention and care. The journey of cancer survivorship is increasingly complex, and the laboratory’s role in navigating its challenges is more critical than ever.